Compare IPAR & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPAR | LQDA |
|---|---|---|
| Founded | 1982 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.4B |
| IPO Year | 1995 | 2020 |
| Metric | IPAR | LQDA |
|---|---|---|
| Price | $95.96 | $61.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | ★ $116.60 | $41.00 |
| AVG Volume (30 Days) | 206.1K | ★ 1.6M |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.54% | N/A |
| EPS Growth | 2.34 | ★ 51.81 |
| EPS | ★ 1.35 | 0.52 |
| Revenue | ★ $1,317,700,000.00 | $158,320,000.00 |
| Revenue This Year | $3.86 | $278.87 |
| Revenue Next Year | $7.89 | $57.13 |
| P/E Ratio | ★ $71.58 | $119.97 |
| Revenue Growth | 21.26 | ★ 1031.18 |
| 52 Week Low | $77.21 | $11.85 |
| 52 Week High | $142.50 | $63.46 |
| Indicator | IPAR | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 60.08 | 74.61 |
| Support Level | $92.30 | $31.23 |
| Resistance Level | $98.64 | N/A |
| Average True Range (ATR) | 2.97 | 3.88 |
| MACD | 0.87 | 0.27 |
| Stochastic Oscillator | 89.54 | 91.16 |
Interparfums Inc operates in the fragrance business and produces and distributes a wide array of prestige fragrance and fragrance-related products. It sells its product under the brand which includes Boucheron, Coach, Jimmy Choo, Karl Lagerfeld, Kate Spade, Lacoste, Lanvin, Moncler, Montblanc, Rochas and Van Cleef & Arpels. The company operates in two operating segments namely European based operations, SA, and United States based operations. The group sells its products to department stores, perfumeries, specialty stores, and domestic and international wholesalers and distributors.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.